Multiple Sclerosis Study

Study Purpose: To investigate the safety and tolerability of a newly approved oral medication for MS treatment versus those on previously approved MS therapies.

Basic Eligibility Criteria:

• Patients male and female ages 18 to 65
• Must have been diagnosed with Relapse Remitting Multiple Sclerosis
• Must be receiving a continuous approved treatment for MS for a minimum of 6 months 

If you would like further information about any of our Clinical Trials at Associated Neurologists of Southern Connecticut, please feel free to contact any of our Research staff:

Angelo Termine, Clinical Research Manager, at atermine@anscneuro.com

Amanda Herrera, Clinical Research Administrative Assistant, at aherrera@anscneuro.com 

or any of our Clinical Research Coordinators: 

Elizabeth Perrotti at eperrotti@anscneuro.com

Grace Castaneda at gcastaneda@anscneuro.com 

Cindy Chu at cchu@anscneuro.com or

Nick Adams at nadams@anscneuro.com or

You may also call 203.333.1151 and we will be happy to answer any of your questions.